DarioHealth Corp. Logo

DarioHealth Corp.

DRIO

(2.0)
Stock Price

0,77 USD

-12.71% ROA

-7.91% ROE

-7.81x PER

Market Cap.

31.679.856,00 USD

43.37% DER

0% Yield

-28.11% NPM

DarioHealth Corp. Stock Analysis

DarioHealth Corp. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

DarioHealth Corp. Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0.5x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock has a minimal amount of debt (44%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 ROE

ROE in an average range (0.15%) suggests satisfactory profitability and decent utilization of shareholders' equity.

4 Revenue Growth

With a track record of continuous revenue growth in the last three years, this company offers a promising investment opportunity

5 Net Profit Growth

Over the last three years, this company has consistently achieved net profit growth, indicating a favorable financial performance and making it an attractive investment option.

6 Buffet Intrinsic Value

The company's stock shows potential as it is undervalued (79) according to Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

7 ROA

The stock's ROA (0%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Graham Number

Based on the Graham number, this company's stock price appears to be higher than its intrinsic value, signaling a potentially unfavorable investment choice.

10 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

11 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

DarioHealth Corp. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

DarioHealth Corp. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

DarioHealth Corp. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

DarioHealth Corp. Revenue
Year Revenue Growth
2012 0
2013 0 0%
2014 51.000 100%
2015 823.000 93.8%
2016 2.803.000 70.64%
2017 5.170.000 45.78%
2018 7.394.000 30.08%
2019 7.559.000 2.18%
2020 7.576.000 0.22%
2021 20.513.000 63.07%
2022 27.656.000 25.83%
2023 14.072.000 -96.53%
2023 20.352.000 30.86%
2024 25.020.000 18.66%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

DarioHealth Corp. Research and Development Expenses
Year Research and Development Expenses Growth
2012 1.501.265
2013 4.912.457 69.44%
2014 3.943.000 -24.59%
2015 2.565.000 -53.72%
2016 2.154.000 -19.08%
2017 3.297.000 34.67%
2018 3.676.000 10.31%
2019 3.692.000 0.43%
2020 4.433.000 16.72%
2021 17.219.000 74.26%
2022 19.649.000 12.37%
2023 22.660.000 13.29%
2023 20.248.000 -11.91%
2024 27.240.000 25.67%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

DarioHealth Corp. General and Administrative Expenses
Year General and Administrative Expenses Growth
2012 2.177.156
2013 6.295.538 65.42%
2014 3.640.000 -72.95%
2015 2.948.000 -23.47%
2016 3.378.000 12.73%
2017 4.726.000 28.52%
2018 5.468.000 13.57%
2019 5.483.000 0.27%
2020 12.756.000 57.02%
2021 23.532.000 45.79%
2022 16.493.000 -42.68%
2023 16.512.000 0.12%
2023 18.140.000 8.97%
2024 20.020.000 9.39%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

DarioHealth Corp. EBITDA
Year EBITDA Growth
2012 -2.343.713
2013 -12.429.607 81.14%
2014 -11.992.000 -3.65%
2015 -7.941.000 -51.01%
2016 -10.410.000 23.72%
2017 -13.071.000 20.36%
2018 -17.384.000 24.81%
2019 -17.502.000 0.67%
2020 -30.159.000 41.97%
2021 -72.982.000 58.68%
2022 -52.394.000 -39.29%
2023 -62.184.000 15.74%
2023 -50.837.000 -22.32%
2024 -56.932.000 10.71%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

DarioHealth Corp. Gross Profit
Year Gross Profit Growth
2012 0
2013 -13.562.398 100%
2014 -2.223.000 -510.09%
2015 -855.000 -160%
2016 -561.000 -52.41%
2017 1.311.000 142.79%
2018 1.765.000 25.72%
2019 2.597.000 32.04%
2020 2.513.000 -3.34%
2021 3.963.000 36.59%
2022 9.655.000 58.95%
2023 2.440.000 -295.7%
2023 5.984.000 59.22%
2024 11.024.000 45.72%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

DarioHealth Corp. Net Profit
Year Net Profit Growth
2012 -5.686.573
2013 -13.931.778 59.18%
2014 -12.877.000 -8.19%
2015 -7.142.000 -80.3%
2016 -10.887.000 34.4%
2017 -15.743.000 30.85%
2018 -17.803.000 11.57%
2019 -17.767.000 -0.2%
2020 -28.987.000 38.71%
2021 -76.761.000 62.24%
2022 -62.193.000 -23.42%
2023 67.616.000 191.98%
2023 -54.860.245 223.25%
2024 -13.475.588 -307.11%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

DarioHealth Corp. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2012 -513
2013 -1.369 62.6%
2014 -534 -156.37%
2015 -75 -612%
2016 -42 -82.93%
2017 -33 -28.13%
2018 -15 -113.33%
2019 -8 -114.29%
2020 -5 -75%
2021 -5 0%
2022 -3 -100%
2023 2 200%
2023 -2 300%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

DarioHealth Corp. Free Cashflow
Year Free Cashflow Growth
2012 -3.517.314
2013 -9.000.096 60.92%
2014 -9.144.000 1.57%
2015 -6.387.000 -43.17%
2016 -9.187.000 30.48%
2017 -10.814.000 15.05%
2018 -11.541.000 6.3%
2019 -15.823.000 27.06%
2020 -17.854.000 11.38%
2021 -50.670.000 64.76%
2022 -48.418.000 -4.65%
2023 -8.926.000 -442.44%
2023 -30.963.000 71.17%
2024 -11.392.000 -171.8%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

DarioHealth Corp. Operating Cashflow
Year Operating Cashflow Growth
2012 -2.982.680
2013 -7.599.723 60.75%
2014 -8.581.000 11.44%
2015 -6.277.000 -36.71%
2016 -8.379.000 25.09%
2017 -10.619.000 21.09%
2018 -11.470.000 7.42%
2019 -15.725.000 27.06%
2020 -17.736.000 11.34%
2021 -50.409.000 64.82%
2022 -47.845.000 -5.36%
2023 -8.645.000 -453.44%
2023 -30.379.000 71.54%
2024 -11.363.000 -167.35%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

DarioHealth Corp. Capital Expenditure
Year Capital Expenditure Growth
2012 534.634
2013 1.400.373 61.82%
2014 563.000 -148.73%
2015 110.000 -411.82%
2016 808.000 86.39%
2017 195.000 -314.36%
2018 71.000 -174.65%
2019 98.000 27.55%
2020 118.000 16.95%
2021 261.000 54.79%
2022 573.000 54.45%
2023 281.000 -103.91%
2023 584.000 51.88%
2024 29.000 -1913.79%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

DarioHealth Corp. Equity
Year Equity Growth
2012 -1.069.043
2013 -86.381 -1137.59%
2014 -2.538.000 96.6%
2015 777.000 426.64%
2016 -6.541.000 111.88%
2017 3.941.000 265.97%
2018 8.925.000 55.84%
2019 18.894.000 52.76%
2020 28.151.000 32.88%
2021 85.549.000 67.09%
2022 79.999.000 -6.94%
2023 68.035.000 -17.59%
2023 58.144.000 -17.01%
2024 68.055.000 14.56%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

DarioHealth Corp. Assets
Year Assets Growth
2012 2.315.453
2013 4.115.814 43.74%
2014 3.081.000 -33.59%
2015 5.077.000 39.31%
2016 3.872.000 -31.12%
2017 6.957.000 44.34%
2018 14.089.000 50.62%
2019 24.569.000 42.66%
2020 35.407.000 30.61%
2021 100.771.000 64.86%
2022 119.191.000 15.45%
2023 106.505.000 -11.91%
2023 96.389.000 -10.49%
2024 122.134.000 21.08%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

DarioHealth Corp. Liabilities
Year Liabilities Growth
2012 3.384.496
2013 4.202.195 19.46%
2014 5.619.000 25.21%
2015 4.300.000 -30.67%
2016 10.413.000 58.71%
2017 3.016.000 -245.26%
2018 5.164.000 41.6%
2019 5.675.000 9%
2020 7.256.000 21.79%
2021 15.222.000 52.33%
2022 39.192.000 61.16%
2023 38.470.000 -1.88%
2023 38.245.000 -0.59%
2024 54.079.000 29.28%

DarioHealth Corp. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.48
Net Income per Share
-0.14
Price to Earning Ratio
-7.81x
Price To Sales Ratio
1.65x
POCF Ratio
-1.04
PFCF Ratio
-0.77
Price to Book Ratio
0.62
EV to Sales
2.01
EV Over EBITDA
-0.66
EV to Operating CashFlow
-0.95
EV to FreeCashFlow
-0.94
Earnings Yield
-0.13
FreeCashFlow Yield
-1.29
Market Cap
0,03 Bil.
Enterprise Value
0,04 Bil.
Graham Number
2.28
Graham NetNet
-0.57

Income Statement Metrics

Net Income per Share
-0.14
Income Quality
1.06
ROE
-0.08
Return On Assets
-0.04
Return On Capital Employed
-0.6
Net Income per EBT
0.27
EBT Per Ebit
0.32
Ebit per Revenue
-3.29
Effective Tax Rate
0.67

Margins

Sales, General, & Administrative to Revenue
1.12
Research & Developement to Revenue
1.22
Stock Based Compensation to Revenue
1.04
Gross Profit Margin
0.31
Operating Profit Margin
-3.29
Pretax Profit Margin
-1.05
Net Profit Margin
-0.28

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-1.02
Free CashFlow per Share
-1.03
Capex to Operating CashFlow
-0.01
Capex to Revenue
0.02
Capex to Depreciation
0.08
Return on Invested Capital
-0.21
Return on Tangible Assets
-0.13
Days Sales Outstanding
128.31
Days Payables Outstanding
92.54
Days of Inventory on Hand
141.75
Receivables Turnover
2.84
Payables Turnover
3.94
Inventory Turnover
2.57
Capex per Share
0.01

Balance Sheet

Cash per Share
0,60
Book Value per Share
1,71
Tangible Book Value per Share
-0.29
Shareholders Equity per Share
1.71
Interest Debt per Share
0.76
Debt to Equity
0.43
Debt to Assets
0.24
Net Debt to EBITDA
-0.12
Current Ratio
2.26
Tangible Asset Value
-0,01 Bil.
Net Current Asset Value
-0,01 Bil.
Invested Capital
104578000
Working Capital
0,02 Bil.
Intangibles to Total Assets
0.65
Average Receivables
0,01 Bil.
Average Payables
0,00 Bil.
Average Inventory
5024500
Debt to Market Cap
0.93

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

DarioHealth Corp. Dividends
Year Dividends Growth

DarioHealth Corp. Profile

About DarioHealth Corp.

DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-specific disposables test strip cartridges, lancets, and blood glucose monitoring systems. It also provides smart glucose meters; bluetooth connected blood pressure cuff; digital scales; biofeedback sensor devices; and diabetes management programs, including lifestyle changes, healthy eating, advanced tracking, and live coaching. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.

CEO
Mr. Erez Raphael
Employee
223
Address
18 West 18th Street
New York, 10011

DarioHealth Corp. Executives & BODs

DarioHealth Corp. Executives & BODs
# Name Age
1 Limor Drezner
Chief People Officer
70
2 Josh Fischer
Senior Vice President of Operations & Compliance
70
3 Ms. Mona Dean
Chief Compliance Officer
70
4 Claudia Levi
Content & Communications Manager
70
5 Mr. Tomer Ben-Kiki
Chief Technology Officer
70
6 Kat Parrella
Investor Relations Manager
70
7 Mr. Zvi Ben David CPA
Chief Financial Officer, Treasurer & Secretary
70
8 Mr. Jean Christophe Muyl
Head of Commercialization North America
70
9 Mr. Erez Raphael
Chief Executive Officer & Director
70
10 Dov Oppenheim
Co-Founder & Production Chief
70

DarioHealth Corp. Competitors